Streetbeat News

Analyst Ratings

MAXN

Maxeon Solar Technologies reported Q2 earnings per share of $(0.03), beating the analyst consensus estimate of $(0.08) by 62.5%. However, the company's quarterly sales of $348.37 million missed the analyst consensus estimate of $372.63 million by 6.51%. This represents a 46.33% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:10 pm

EVLV

Evolv Technologies reported Q2 earnings per share of $(0.10), beating the analyst consensus estimate of $(0.11) by 9.09%. The company also reported quarterly sales of $19.80 million, surpassing the analyst consensus estimate of $14.28 million by 38.66%. This represents a 118.30% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:10 pm

ONTX

Onconova Therapeutics reported Q2 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.31) by 35.48%. However, the company's quarterly sales of $57.00K missed the estimate of $70.00K by 18.57%.

Portfolio Pulse from totan@benzinga.com

August 10, 2023 | 8:09 pm

LCTX

Lineage Cell Therapeutics reported Q2 earnings per share (EPS) of $(0.03), beating the analyst consensus estimate of $(0.04) by 25%. The company also reported quarterly sales of $3.23 million, surpassing the analyst consensus estimate of $2.20 million by 46.59%. However, this represents a 29.17% decrease in sales compared to the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 10, 2023 | 8:09 pm

YMAB

Y-mAbs Therapeutics reported Q2 earnings per share (EPS) of $(0.14), beating the analyst consensus estimate of $(0.24) by 41.67%. The company also reported quarterly sales of $20.80 million, surpassing the analyst consensus estimate of $20.35 million by 2.21%. Both EPS and sales figures represent significant increases over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:08 pm

RGTI

Rigetti Computing (NASDAQ:RGTI) reported Q2 losses of $(0.13) per share, beating the analyst consensus estimate of $(0.17) by 23.53%. The company also reported quarterly sales of $3.33 million, surpassing the analyst consensus estimate of $2.75 million by 20.98%. This represents a 55.90% increase over sales of $2.13 million from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:07 pm

XAIR

Beyond Air (NASDAQ:XAIR) reported Q1 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.47) by 4.26%. However, this represents a 21.62% decrease over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:07 pm

SNES

SenesTech reported Q2 losses of $(0.70) per share, beating the analyst consensus estimate of $(0.78) by 10.26%. However, the company's quarterly sales of $305.00K missed the analyst consensus estimate of $360.00K by 15.28%. This represents a 10.11% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 10, 2023 | 8:06 pm

FORA

Forian (NASDAQ:FORA) reported Q2 losses of $(0.03) per share, beating the analyst consensus estimate of $(0.05) by 40 percent. However, the company's quarterly sales of $4.89 million missed the analyst consensus estimate of $5.10 million by 4.06 percent.

Portfolio Pulse from vinayak@benzinga.com

August 10, 2023 | 8:05 pm

BTTX

Lake Street analyst Thomas Flaten maintains a 'Buy' rating on Better Therapeutics (NASDAQ:BTTX), but has lowered the price target from $5 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:04 pm